Basilea Pharmaceutica Ltd. Logo
 

Anti-Infectives 2015

 
 
 

Isavuconazole

  • Ananda-Rajah MR, Kontoyiannis D. Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiol 2015; 10(5): 693-708.
  • Bassetti M, Carnelutti A, Righi E, Corcione S, Rosa De FG. Current Pharmacological Treatment of Pulmonary Aspergillosis. Clin Pulmy Med. 2015; 22(5): 205–214.
  • Cornely OA, Böhme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study. Antimicrob Agents Chemother. 2015; 59(4): 2078-2085.
  • Engelhardt M, Khandelwal N, Franks B, Shi F, Spalding J, Azie N. HEOR analysis of patients in SECURE trial comparing isavuconazole to voriconazole for primary treatment of invasive fungal disease caused by Aspergillus and other filamentous fungi. Mycoses. 2015; 58(S4): 198.
  • Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee D-G, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson III GR, Lee M, Maher RM, Schmitt-Hoffmann A-H, Zeiher B, Ullmann AJ. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. The Lancet (published in the December 9th 2015 online issue).
  • Maertens JA, Patterson T, Rahav G, Kontoyiannis DP, Marr K, Maher R, Lee M, Zeiher B, Ullmann A. Phase 3 randomized, double-blind trial evaluating isavuconazole vs. voriconazole for primary treatment of invasive fungal disease caused by aspergillus Spp. or other filamentous fungi (SECURE). Mycoses. 2015; 58(S4): 196.
  • Marty FM, Perfect J, Cornely OA, Mullane KM, Rahav G, Lee M, Ito M, Maher R, Zeiher B, Ostrosky-Zeichner L. An open-label phase 3 study of isavuconazole (VITAL): Focus on mucormycosis. Mycoses. 2015; 58(S4): 198-199.
  • McCormack PL. Isavuconazonium: First Global Approval. Drugs. 2015; 75(7): 817-822.
  • Miceli MH, Kauffman CA. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis 2015.
  • Pfaller MA, Rhomberg PR, Messer SA, Jones RN, Castanheira M. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. Diagn Microbiol Infect Dis. 2015; 82(4): 303-313.
  • Slain D, Cleary JD. Isavuconazonium Sulfate: a Novel Antifungal Agent. Curr Fung Infect Reports 2015; 9(4): 302-313.
  • Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffmann AH. Drug interaction profiles of isavuconazole, voriconazole and posaconazole with immunosuppressants metabolized by CYP4503A4 (CYP3A4). Mycoses. 2015; 58(S4): 218-219.
  • Vehreschild MJGT, Vehreschild JJ, Marty FM, Perfect J, Ostrosky-Zeichner L, Rahav G, Zeiher B, Lee M, Maher R, Lovell C, Engelhardt M, Cornely OA. Primary treatment of invasive mucormycosis (IM) with isavuconazole (VITAL Study) or amphotericin formulations (FungiScope™): Case matched analysis. Mycoses. 2015; 58(S4): 197.
  • Viljoen J, Azie N, Schmitt-Hoffmann AH, Ghannoum M. A Phase 2, Randomized, Double-Blind, Multi-Center Trial to Evaluate the Safety and Efficacy of Three Dosing Regimens of Isavuconazole Compared With Fluconazole in Patients with Uncomplicated Esophageal Candidiasis. Antimicrob Agents Chemother. 2015; 59(3): 1671-1679.

  • ECCMID, 2015, EP018 / A comparison of the safety profiles of Isavuconazole vs voriconazole in the phase 3 SECURE study in patients with invasive mould infections. Ullmann AJ, Selleslag D, Heinz WJ, Herbrecht R, Rahav G, Giladi M, Aoun M, Cornely OA,  Azie N, Kaufhold A, Engelhardt M, Maertens J.
  • ECCMID, 2015, EV-0932 / Safety and outcomes in invasive aspergillosis patients with renal vs. no renal impairment treated with Isavuconazole: experience from the SECURE (randomized) and VITAL trials. Mullane M, Aoun M, Franks B, Azie N, Mujais S, Kaufhold A, Maertens J.

  • TIMM, 2015, P408 / Economic Outcome Analysis of Patients Randomised in the SECURE Phase 3 Trial Comparing Isavuconazole to Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi. Engelhardt M, Khandelwal N, Franks B, Shi F, Spalding J, Azie N. Health
  • TIMM, 2015, P409 / Marty FM, Perfect JR, Cornely OA, Mullane KM, Rahav G, Lee M, Ito M, Maher R, Zeiher B, Ostrosky-Zeichner L. An Open-Label Phase 3 Study of Isavuconazole (VITAL): Focus on Mucormycosis.
  • TIMM, 2015, P464 / Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffmann AH. Drug Interaction Profiles of Isavuconazole, Voriconazole and Posaconazole with Immunosuppressants Metabolised by CYP450 3A4.

 

Ceftobiprole

  • Kresken M, Koerber-Irrgang B, Hafner D. Susceptibility to ceftobiprole in blood and respiratory isolates collected from hospitalized patients prior to the introduction of this group 5 cephalosporin: Results of the PEG study. Int J Med Microbiol. 2015; 305 (S1): 71.
 
Info